North America Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type [Long Acting Insulin, Rapid Acting Insulins, Short-Acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar I

North America Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type [Long Acting Insulin, Rapid Acting Insulins, Short-Acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-Like Peptide-1 (GLP-1), Pens and Needles, and Others]

The insulin market in North America is expected to grow from US$ 23,946.85 million in 2022 to US$ 43,517.93 million by 2028. It is estimated to grow at a CAGR of 10.5% from 2022 to 2028.
Rapid Technological Developments in Insulin Delivery Devices by Major Players Boosts
As the prevalence of diabetes is increasing across North America, the demand for more advanced therapeutic products is on the rise. Companies in the insulin market actively support public and private research and academic institutes for encouraging research activities. A few of the recent developments related to rapid technological advancements in the insulin market are mentioned below:

In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin injection, BC Lispro. Currently, the drug is in phase III clinical trial initiated in China.

In May 2021, Bigfoot Biomedical received 510(k) clearance from the USFDA for its Bigfoot Unity Diabetes Management System offered with connected smart pen caps that recommend insulin doses for people using the multiple daily injections (MDI) therapy.
Such technological advancements in insulin delivery devices are boosting the growth of the North America insulin market.

Market Overview

The North America insulin market has been segmented into the US, Canada, and Mexico, wherein the US accounts for a maximum share. The market growth in the region is attributed to the rising prevalence of diabetes and obesity, coupled with the increasing awareness about diabetes care. According to the National Diabetes Statistics Report 2020, ~30.3 million people in the US have diabetes, representing 94% of the total population. Among the diabetic population, ~5% are diagnosed with type 1 diabetes while 90–95% have type 2 diabetes. From more than 30 million Americans with diabetes, ~7.4 million rely on insulin to manage their condition. In addition, data also revealed ~86 million adults aged 18 or above and ~23.1 million elders of age 65 were prediabetic. Diabetes is also a leading cause of blindness and end-stage renal diseases or renal failure among adults.
North America Insulin Market Revenue and Forecast to 2028 (US$ Million)

North America Insulin Market Segmentation

The North America insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin and traditional human insulin, concentrated insulin and combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen and needle, and others. The long acting insulin segment accounted for the largest market share in 2022.
The North America insulin market for the long acting insulin segment is subsegmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment held the largest market share in 2022.
The North America insulin market for the short acting insulin and traditional human insulin segment is subsegmented into Novolin R, Humalin R, Insuman, and others. The insuman segment held the largest market share in 2022.
The North America insulin market for the concentrated insulin and combination insulin segment is further segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.
The North America insulin market for the biosimilar insulin segment is further segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment accounted for a larger market share in 2022.
Based on country, the insulin market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

Reasons to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America insulin market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America insulin market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution